Clinical Trial Update: Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab in combination with chemotherapy and antiangiogenic agents for non-small cell lung cancer after failure of prior PD-1/PD-L1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer Recurrent | Phase 2 | Status: UNKNOWN